© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Ghassan K. Abou-Alfa, MD, MBA, reviews key clinical trial data and treatment options for the management of unresectable HCC.
June 23rd 2021
Ghassan K. Abou-Alfa, MD, MBA, presents the case of a 68-year-old man with hepatocellular carcinoma (HCC) and shares his initial impressions.
An expert in gastrointestinal oncology comments on approaching first-line therapy for a patient with previously untreated, unresectable HCC and reviews key findings from the IMbrave150 trial.
Dr Ghassan K. Abou-Alfa provides insight from the results of the REFLECT trial comparing sorafenib vs lenvatinib in patients with unresectable HCC and comments on the safety profile of lenvatinib.
Gastrointestinal oncology expert, Dr Ghassan K. Abou-Alfa, discusses future directions and promising novel approaches under investigation for the treatment of unresectable HCC.
Ghassan K. Abou-Alfa, MD, MBA, shares clinical pearls and advice for the management of patients with unresectable HCC.